Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
Barbara Merelli(Ospedale Papa Giovanni XXIII), Mario Mandalà(University of Perugia), Daniela Massi(University of Florence), Laura Cattaneo(Ospedale Papa Giovanni XXIII)
Cited by 170
Related Papers
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k